Genomic Instability in Acute Transformation of Chronic Myelogenous Leukemia.
10.7534/j.issn.1009-2137.2015.04.057
- Author:
Su-Qing GUO
1
;
Ying-Hua LI
2
Author Information
1. Department of Hematology, Hengshui Harlson International Peace Hospital, Hengshui 053000, Hebei Province, China.
2. Department of Hematology, Hengshui Harlson International Peace Hospital, Hengshui 053000, Hebei Province, China. E-mail: 1445828799@qq.com.
- Publication Type:Journal Article
- MeSH:
Blast Crisis;
Drug Resistance, Neoplasm;
Genomic Instability;
Humans;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- From:
Journal of Experimental Hematology
2015;23(4):1199-1202
- CountryChina
- Language:Chinese
-
Abstract:
Chronic myeloid leukemia (CML) is a myeloproliferative disorder, characterized by excessive proliferation of myeloid cells. CML patients in early phase [also known as chronic phase (CP)] usually respond to treatment with tyrosine kinase inhibitors (TKI), some patients respond initially to TKI, but later become resistant, then resulting in the transformation from CP to more advanced phase, which were subclassified as either accelerated phase or blastic phase. At present, the molecular mechanisms of CML have been not yet clear, and acute transformation has been not fully understood, studies have shown that genomic instability promotes the acute conversion of CML. This review discusses the molecular mechanisms leading to the transformation of CML, and some therapeutic approaches.
